Breast cancer trial with erythropoietin terminated unexpectedly

Lancet Oncology

Volumn 4, Issue 8, 2003, Pages 459-460

  Leyland Jones, Brian ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST METASTASIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NOTE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; THROMBOSIS; VASCULAR DISEASE;

EID: 0041976976     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(03)01163-X     Document Type: Letter

References (6)

1. Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999; 86: 1528-36.
2. Thews O, Koenig R, Kelleher DK, et al. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 1998; 78: 752-56.
3. Silver DF and Piver MS. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol 1999; 73: 280-84.
4. Glaser CM, Millesi W, Kornek GV, et al. impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001; 50: 705-15.
5. Antonadou D, Cardamakis E, Puglisi M, et al. Erythropoietin enhances radiation treatment efficacy in patients with pelvic malignancies: final results of a randomized phase III study. Eur J Cancer 2001; 37 (suppl 6): 144 (abstr 530).
6. Littlewood TJ, Bajetta E, Nortier JWR, et al for the Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19: 2865-74.